Abstract
AbstractPrognostic analysis for early-stage (stage I/II) melanomas is of paramount importance for customized surveillance and treatment plans. Since immune checkpoint inhibitors have recently been approved for stage IIB and IIC melanomas, prognostic tools to identify patients at high risk of recurrence have become even more critical. This study aims to assess the effectiveness of machine-learning algorithms in predicting melanoma recurrence using clinical and histopathologic features from Electronic Health Records (EHRs). We collected 1720 early-stage melanomas: 1172 from the Mass General Brigham healthcare system (MGB) and 548 from the Dana-Farber Cancer Institute (DFCI). We extracted 36 clinicopathologic features and used them to predict the recurrence risk with supervised machine-learning algorithms. Models were evaluated internally and externally: (1) five-fold cross-validation of the MGB cohort; (2) the MGB cohort for training and the DFCI cohort for testing independently. In the internal and external validations, respectively, we achieved a recurrence classification performance of AUC: 0.845 and 0.812, and a time-to-event prediction performance of time-dependent AUC: 0.853 and 0.820. Breslow tumor thickness and mitotic rate were identified as the most predictive features. Our results suggest that machine-learning algorithms can extract predictive signals from clinicopathologic features for early-stage melanoma recurrence prediction, which will enable the identification of patients that may benefit from adjuvant immunotherapy.
Funder
U.S. Department of Defense
Dermatology Foundation
Publisher
Springer Science and Business Media LLC
Reference71 articles.
1. CDC. Melanoma Incidence and Mortality, United States—2012–2016 (Centers for Disease Control and Prevention, US Department of Health and Human Services, 2012–2016).
2. Bajaj, S. et al. Melanoma prognosis: accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. J. Natl Cancer Inst. 112, 921–928 (2020).
3. Freeman, M. & Laks, S. Surveillance imaging for metastasis in high-risk melanoma: importance in individualized patient care and survivorship. Melanoma Manag. 6, MMT12 (2019).
4. FDA. FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC Melanoma (United States Food and Drug Administration, 2021).
5. Tang, K. et al. Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy. JAMA Dermatol. 158, 189–193 (2022).
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献